Endocrine sequelae of cancer and cancer treatments

Stava, Charles; Jiménez, Camilo; Vassilopoulou‐Sellin, Rena

doi:10.1007/s11764-007-0038-6

Cited by 32 publications

(35 citation statements)

References 168 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…67 A direct explanation for this is not yet available, but it is hypothesized that hormonal alterations induce obesity, which subsequently induces insulin resistance and other components of the metabolic syndrome. Alternatively, hormonal alterations might be induced by obesity.…”

Section: Discussionmentioning

confidence: 99%

Metabolic syndrome in childhood cancer survivors.

Subramani

Scott

Sneha

et al. 2017

JCO

View full text Add to dashboard Cite

145 Background: Reavan in 1988 noted that several risk factors for cardiovascular diseases commonly cluster together, and he recognised them as a disease, named syndrome X, currently known as metabolic syndrome. Metabolic syndrome is a group of disorders related to insulin resistance, characterized clinically by central obesity, hyperglycemia, dyslipidemia and hypertension. There is a growing body of evidence indicating that pediatric cancer survivors are at a greater risk of developing metabolic syndrome. We studied the prevalence of metabolic syndrome in children with cancer who completed their treatment and on follow up. Methods: All relevant past medical data (of the disease, treatment and all events) were collected from the medical records. Tanner staging was perfomred, height was measured using a Harpenden stadiometer. Weight/WAIST circumference were measured. The body mass index (BMI) was calculated as weight (kg)/(height (m)²). BMI ≥90thcentile as per CDC chart was taken as abnormal. Blood pressure was measured on the right arm of the patient. Presence of family history of diabetes, cardiovascular diseases and hypercholesterolemia were taken. Fasting Blood sugar, insulin, HbA1C, lipid profile were done. We used IDF(International diabetes federation) criteria to assess the metabolic syndrome among cancer survivors. This study was approved by our university ethics comittee. Results: Seventy five children who fulfilled the inclusion criteria were included in this study. Out of which 48 were males and 27 were females. Among these, majority of children are treated for acute lymphoblastic leukemia. 8.25% of total population satisfied the criteria of metabolic syndrome. Age, gender, diagnosis, modality of treatment were not to be of statistical significance, however majority of children with metabolic syndrome are in adolescent group. Conclusions: With the better care committed to children with cancer even in developing country, the survival rates are greatly improving and so metabolic syndrome is becoming the major target for intervention in the follow up of cancer survivors. As metabolic syndrome cannot treated by a single drug therapy, it is necessary to have cancer survivors follow up screening.

show abstract

Section: Discussionmentioning

confidence: 99%

Metabolic syndrome in childhood cancer survivors.

Subramani

Scott

Sneha

et al. 2017

JCO

View full text Add to dashboard Cite

show abstract

“…In adult survivors of childhood cancers, endocrine toxicity, including thyroid disorders, is a common long-term complication of cytotoxic treatments (9). Conversely, cytotoxic treatments seem to alter thyroid function in a relatively small portion of adult patients (5).…”

Section: Thyroid and Cytotoxic Anticancer Agentsmentioning

confidence: 99%

Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs

Torino

Barnabei²,

Paragliola

et al. 2013

Thyroid

103

View full text Add to dashboard Cite

“…In the present study, we found normal BMI and normal percentage fat in NHL survivors. Hypothyroidism, which can contribute to obesity and is reported in survivors, especially after local radiotherapy [49][50][51], did not occur in this group of survivors.…”

Section: Discussionmentioning

confidence: 50%

Endocrine late sequelae in long-term survivors of childhood non-Hodgkin lymphoma

Waas

Neggers²,

Winkel

et al. 2012

Annals of Oncology

View full text Add to dashboard Cite

Background: Aim of this study was to investigate the long-term endocrine effects of treatment of childhood non-Hodgkin lymphoma (NHL). Patients and methods:A single-center cohort of 84 survivors (22 females) was included in this retrospective study.Median age was 21 years (9-40 years) and time after cessation of therapy 12 years (4-30 years). Height, weight, percentage fat, lean body mass (LBM), bone mineral content (BMC), bone mineral density of total body (BMD TB ) and bone mineral density of lumbar spine (BMD LS ) were measured. Thyroid-stimulating hormone (TSH), free thyroxin (fT4), insulin-like growth factor-1 (IGF-1), inhibin B and anti-mü llerian hormone (AMH) levels were measured. Results were compared with Dutch controls.Results: Height was lower in survivors [mean standard deviation score (SDS) 20.36, P = 0.002], but further analysis showed that shorter stature was already present at diagnosis (mean SDS 20.28, P = 0.023). Body mass index, percentage fat, BMC, BMD TB and BMD LS were not different from controls. LBM was lower in survivors (mean SDS 20.47, P = 0.008). TSH, fT4 and IGF-1 were normal in all survivors. Three of 20 adult females had low AMH levels and 23 of 42 adult males had low inhibin B levels.Conclusions: Twelve years after cessation of treatment, NHL survivors did not develop adiposity, osteoporosis or thyroid disease. Male survivors may be at risk for infertility.

show abstract

Endocrine sequelae of cancer and cancer treatments

Abstract: Recognition and awareness of endocrine sequelae of cancer treatments may permit for early detection and appropriate follow-up care for cancer survivors, thus improving their overall health and quality of life.

Cited by 32 publications

References 168 publications

Metabolic syndrome in childhood cancer survivors.

Metabolic syndrome in childhood cancer survivors.

Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs

Endocrine late sequelae in long-term survivors of childhood non-Hodgkin lymphoma

Contact Info

Product

Resources

About